Opko Health, Inc. (NASDAQ:OPK) is reporting third quarter earnings results on Thursday 29th October 2020, after market close.
The consensus estimates from Thomson Reuters are income of $ 0.05 per share.
For the full year, analysts predict revenues of $ 1284.34 million, while looking forward to income of $ 0.05 per share.
Previous Quarter Performance
Opko Health, Inc. unfold income for the second quarter of $ 0.05 per share, from the revenue of $ 301.20 million. The quarterly revenues improved 33.06 percent compared with the same quarter last year. According to street consensus, OPK was expected to report 2Q20 loss of $ 0.07 per share from revenue of $ 245.60 million. The bottom line results beat street analysts by $ 0.12 or 171.43 percent, at the same time, top line results outshined analysts by $ 55.60 million or 22.64 percent.
Stock Performance
Shares of Opko Health, Inc. traded low $ -0.14 or -3.38 percent on Wednesday, reaching $ 4.00 with volume of 8.66 million shares. Opko Health, Inc. has traded high as $ 4.13 and has cracked $ 3.92 on the downward trend
According to the previous trading day, closing price of $ 4.00, representing a 269.64 % increase from the 52 week low of $ 1.12 and a 36.01 % decrease over the 52 week high of $ 6.47.
The company has a market capital of $ 2.68 billion and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Conference Call
Opko Health, Inc. will be hosting a conference call at 4:30 PM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.opko.com
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The companys Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform.
